Search hospitals

>

Ohio

>

Toledo

St. Vincent Mercy Medical Center

Claim this profile

Toledo, Ohio 43608

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Cancer

Conducts research for Pancreatic Cancer

Conducts research for Breast cancer

334 reported clinical trials

4 medical researchers

Photo of St. Vincent Mercy Medical Center in ToledoPhoto of St. Vincent Mercy Medical Center in ToledoPhoto of St. Vincent Mercy Medical Center in Toledo

Summary

St. Vincent Mercy Medical Center is a medical facility located in Toledo, Ohio. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Pancreatic Cancer, Breast cancer and other specialties. St. Vincent Mercy Medical Center is involved with conducting 334 clinical trials across 483 conditions. There are 4 research doctors associated with this hospital, such as Timothy D. Moore, Osama Zaidat, MD, Ameer Kabour, and Adnan R Alkhalili.

Area of expertise

1

Breast Cancer

Global Leader

St. Vincent Mercy Medical Center has run 68 trials for Breast Cancer. Some of their research focus areas include:

ER positive
Stage IV
Stage II
2

Lung Cancer

Global Leader

St. Vincent Mercy Medical Center has run 39 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at St. Vincent Mercy Medical Center

Lung Cancer

Bladder Cancer

Melanoma

Cutaneous Melanoma

Bladder Carcinoma

Esophageal cancer

Multiple Myeloma

Cancer

Breast Cancer

Uterine Cancer

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

Recruiting

2 awards

Phase 3

28 criteria

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at St. Vincent Mercy Medical Center?

Where is St. Vincent Mercy Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does St. Vincent Mercy Medical Center accept?

What awards or recognition has St. Vincent Mercy Medical Center received?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security